“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway

Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in signal transduction initiated by a wide range of membrane receptors. Among the proteins in this family JAK2 has been associated with important downstream proteins, including signal transducers and activators of transcription (STATs), which in turn regulate the expression of a variety of proteins involved in induction or prevention of apoptosis. Therefore, the JAK/STAT signaling axis plays a major role in the proliferation and survival of different cancer cells, and may even be involved in resistance mechanisms against molecularly targeted drugs. Despite extensive research focused on the protein structure and mechanisms of activation of JAKs, and signal transduction through these proteins, their importance in cancer initiation and progression seem to be underestimated. This manuscript is an attempt to highlight the role of JAK proteins in cancer biology, the most recent developments in targeting JAKs, and the central role they play in intracellular cross-talks with other signaling cascades.

[1]  C. Xiong,et al.  Mechanisms of Oral Bacterial Virulence Factors in Pancreatic Cancer , 2019, Front. Cell. Infect. Microbiol..

[2]  J. A. Yunes,et al.  Deleterious and Oncogenic Mutations in the IL7RA , 2019, Cancers.

[3]  F. Musumeci,et al.  An Update on JAK Inhibitors. , 2019, Current medicinal chemistry.

[4]  F. Passamonti,et al.  The role of JAK2 inhibitors in MPNs 7 years after approval. , 2018, Blood.

[5]  P. Zhou,et al.  Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms. , 2018, International journal of biological macromolecules.

[6]  Yunxia Li,et al.  Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes. , 2018, Clinical and experimental rheumatology.

[7]  A. Mead,et al.  Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. , 2017, The Lancet. Haematology.

[8]  A. Look,et al.  Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia , 2017, British journal of haematology.

[9]  N. Saki,et al.  Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis , 2017, Clinical and Translational Oncology.

[10]  Li Shen,et al.  Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo , 2017, BMC Complementary and Alternative Medicine.

[11]  T. Decker,et al.  Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses , 2017, Front. Immunol..

[12]  S. Schreiber,et al.  Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial , 2017, The Lancet.

[13]  S. Verstovsek,et al.  A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis , 2017, Haematologica.

[14]  J. Kremer,et al.  Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) , 2016, Annals of the rheumatic diseases.

[15]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[16]  Y. Asmann,et al.  Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis. , 2016, Cancer research.

[17]  Yoshiya Tanaka,et al.  Baricitinib for the treatment of rheumatoid arthritis , 2016, Expert review of clinical immunology.

[18]  R. Gonzalez-Perez,et al.  Leptin-Induced JAK/STAT Signaling and Cancer Growth , 2016, Vaccines.

[19]  Cheuk-Kwan Sun,et al.  AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia , 2016, Journal of Inflammation.

[20]  L. Seymour,et al.  A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191 , 2016, Leukemia & lymphoma.

[21]  Robert Wolk,et al.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. , 2016, Journal of the American Academy of Dermatology.

[22]  Jin Ju Lee,et al.  Influence of platelet-activating factor receptor (PAFR) on Brucella abortus infection: implications for manipulating the phagocytic strategy of B. abortus , 2016, BMC Microbiology.

[23]  M. Hallek,et al.  Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group , 2016, Leukemia & lymphoma.

[24]  J. Duyster,et al.  Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR , 2016, Annals of Hematology.

[25]  P. Yue,et al.  Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. , 2016, Cancer research.

[26]  M. Iwasaki,et al.  Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study , 2015, Annals of the rheumatic diseases.

[27]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[28]  Seong-Jin Kim,et al.  Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer , 2015, Oncotarget.

[29]  Wen Zhou,et al.  The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer , 2015, Front. Endocrinol..

[30]  R. Hoffman,et al.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. , 2015, Journal of Clinical Oncology.

[31]  J. Cortes,et al.  Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. , 2015, JAMA oncology.

[32]  B. Goh,et al.  Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Gui‐qing Li,et al.  STAT1-Mediated Down-Regulation of Bcl-2 Expression Is Involved in IFN-γ/TNF-α–Induced Apoptosis in NIT-1 Cells , 2015, PloS one.

[34]  Y. Bang,et al.  Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[35]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[36]  R. Fleischmann,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[37]  M. Kaminski,et al.  Activating STAT6 mutations in follicular lymphoma. , 2015, Blood.

[38]  Jianping Xie,et al.  Biology of IL-27 and its Role in the Host Immunity against Mycobacterium Tuberculosis , 2015, International journal of biological sciences.

[39]  Xinchen Sun,et al.  STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma , 2015, Tumor Biology.

[40]  V. Shi,et al.  Interleukin‐4 up‐regulation of epidermal interleukin‐19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (Stat6) to the imperfect Stat6 sites , 2014, Immunology.

[41]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[42]  T. Rausch,et al.  The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse , 2014, Haematologica.

[43]  G. Gallia,et al.  TLR9 is critical for glioma stem cell maintenance and targeting. , 2014, Cancer research.

[44]  Xia Li,et al.  JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. , 2014, Neuro-oncology.

[45]  C. Creighton,et al.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.

[46]  N. Nicola,et al.  The molecular regulation of Janus kinase (JAK) activation. , 2014, The Biochemical journal.

[47]  Donald J Buchsbaum,et al.  Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. , 2014, Cancer letters.

[48]  E. Lee,et al.  Tofacitinib versus methotrexate in rheumatoid arthritis. , 2014, The New England journal of medicine.

[49]  Guillermo A. Gomez,et al.  Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor , 2014, Science.

[50]  Kyung-Su Park,et al.  JAK2-STAT3 Blockade by AG490 Suppresses Autoimmune Arthritis in Mice via Reciprocal Regulation of Regulatory T Cells and Th17 Cells , 2014, The Journal of Immunology.

[51]  W. Leonard,et al.  Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.

[52]  Linyi Chen,et al.  A Network Map of FGF-1/FGFR Signaling System , 2014, Journal of signal transduction.

[53]  K. Hideg,et al.  HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. , 2014, Cancer research.

[54]  H. Kantarjian,et al.  Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. , 2014, Leukemia research.

[55]  Shaomu Chen,et al.  Functional Polymorphisms in Interleukin-23 Receptor and Susceptibility to Esophageal Squamous Cell Carcinoma in Chinese Population , 2014, PloS one.

[56]  R. Schreiber,et al.  Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis , 2013, Cell Death and Differentiation.

[57]  M. Stern,et al.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia , 2014, Leukemia.

[58]  Jiyeon Lee,et al.  Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids. , 2014, American journal of physiology. Endocrinology and metabolism.

[59]  A. Stemmer-Rachamimov,et al.  EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors , 2014, Oncogene.

[60]  M. Pesu,et al.  Therapeutic targeting of the Jak/STAT pathway. , 2014, Basic & clinical pharmacology & toxicology.

[61]  N. Reich.  STATs get their move on. , 2013, JAK-STAT.

[62]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[63]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[64]  E. Plimack,et al.  AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. , 2013, The oncologist.

[65]  Sean C. Bendall,et al.  viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.

[66]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[67]  A. Flores-Morales,et al.  Estrogens Regulate the Hepatic Effects of Growth Hormone, a Hormonal Interplay with Multiple Fates , 2013, Front. Endocrinol..

[68]  S. Langabeer,et al.  Transient JAK2 V617F mutation in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone , 2013, British journal of haematology.

[69]  Tumour heterogeneity: The rise of the minority , 2013, Nature Reviews Cancer.

[70]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[71]  D. Kufe.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches , 2013, Oncogene.

[72]  M. VanSaun.  Molecular Pathways Molecular Pathways : Adiponectin and Leptin Signaling in Cancer , 2013 .

[73]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[74]  Clifford Liongue,et al.  Evolution of the JAK-STAT pathway , 2013, JAK-STAT.

[75]  Jihe Zhao,et al.  The Role of chemokine receptor CXCR4 in breast cancer metastasis. , 2013, American journal of cancer research.

[76]  H. Takeshima,et al.  Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression , 2013, Brain Tumor Pathology.

[77]  R. Levine,et al.  JAK2 the future: therapeutic strategies for JAK-dependent malignancies. , 2012, Trends in pharmacological sciences.

[78]  A. Duschl,et al.  STAT6-dependent and -independent mechanisms in Th2 polarization , 2012, European journal of immunology.

[79]  J. Grandis,et al.  Nucleic acid-based approaches to STAT inhibition , 2012, JAK-STAT.

[80]  D. Görlich,et al.  The Permeability of Reconstituted Nuclear Pores Provides Direct Evidence for the Selective Phase Model , 2012, Cell.

[81]  Z. Amini-Vaughan,et al.  Therapeutic Strategies for Harnessing Human Eosinophils in Allergic Inflammation, Hypereosinophilic Disorders, and Cancer , 2012, Current Allergy and Asthma Reports.

[82]  Simion I. Chiosea,et al.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. , 2012, Cancer discovery.

[83]  Akhilesh Pandey,et al.  A pathway map of prolactin signaling , 2012, Journal of Cell Communication and Signaling.

[84]  Bozena Kaminska,et al.  Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells , 2012, Cancer biology & therapy.

[85]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[86]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[87]  M. Siddiqui,et al.  The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response , 2012, JAK-STAT.

[88]  K. Garcia,et al.  The composition and signaling of the IL-35 receptor are unconventional , 2012, Nature Immunology.

[89]  D. Harrison,et al.  The Jak/STAT pathway. , 2012, Cold Spring Harbor perspectives in biology.

[90]  P. Dobrzanski,et al.  Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer , 2012, Molecular Cancer Therapeutics.

[91]  H. Okada,et al.  MicroRNAs and STAT interplay. , 2012, Seminars in cancer biology.

[92]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[93]  Simion I. Chiosea,et al.  First-inHuman Trial of a STAT 3 Decoy Oligonucleotide in Head and Neck Tumors : Implications for Cancer Therapy , 2012 .

[94]  C. Vaillancourt,et al.  Phosphorylation of JAK2 by serotonin 5-HT (2A) receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell. , 2011, Placenta.

[95]  Guido Gerken,et al.  Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. , 2011, Gastroenterology.

[96]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[97]  J. Lin,et al.  TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21 , 2011, Leukemia.

[98]  S. Hubbard,et al.  The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling , 2011, Nature Structural &Molecular Biology.

[99]  A. Magliocco,et al.  Simultaneous siRNA Targeting of Src and Downstream Signaling Molecules Inhibit Tumor Formation and Metastasis of a Human Model Breast Cancer Cell Line , 2011, PloS one.

[100]  D. Carbone,et al.  Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[101]  Bao-xue Yang,et al.  Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo. , 2011, Asian journal of andrology.

[102]  Naoki Asao,et al.  Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. , 2011, The Journal of investigative dermatology.

[103]  M. Furihata,et al.  AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells , 2010, Molecular Cancer Therapeutics.

[104]  L. Pfeffer,et al.  Cancer esearch apeutics , Targets , and Chemical Biology Induces miR-21 through a Signal Transducer and ivator of Transcription 3 – Dependent Pathway as a R pressive Negative Feedback on IFN-Induced Apoptosis , 2010 .

[105]  E. Reddy,et al.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. , 2010, Genes & cancer.

[106]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[107]  Kevin Struhl,et al.  STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. , 2010, Molecular cell.

[108]  D. Erdmann,et al.  Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 , 2010, Molecular Cancer Therapeutics.

[109]  J. Gotlib,et al.  JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms , 2010, Expert review of hematology.

[110]  J. Heath,et al.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.

[111]  R. Moriggl,et al.  Stat5 Promotes Survival of Mammary Epithelial Cells through Transcriptional Activation of a Distinct Promoter in Akt1 , 2010, Molecular and Cellular Biology.

[112]  S. Batra,et al.  Mucin-interacting proteins: from function to therapeutics. , 2010, Trends in biochemical sciences.

[113]  N. Verma,et al.  STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL , 2010, Cellular & Molecular Biology Letters.

[114]  Z. Estrov,et al.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2010, Blood.

[115]  T. Jiang,et al.  TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients , 2010, BMC Cancer.

[116]  Frédérick A. Mallette,et al.  SOCS1 links cytokine signaling to p53 and senescence. , 2009, Molecular cell.

[117]  E. Manser,et al.  Stat3 promotes directional cell migration by regulating Rac1 activity via its activator βPIX , 2009, Journal of Cell Science.

[118]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[119]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[120]  Sadakazu Aiso,et al.  Targeting the JAK2/STAT3 axis in Alzheimer's disease , 2009, Expert opinion on therapeutic targets.

[121]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[122]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[123]  A. Andoh,et al.  Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease , 2009, The Journal of Immunology.

[124]  Y. Agazie,et al.  Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation* , 2009, Journal of Biological Chemistry.

[125]  J. S. Rao,et al.  Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. , 2009, International journal of oncology.

[126]  D. Banerjee,et al.  Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell‐Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell‐Conditioned Medium , 2009, Stem cells.

[127]  M. Kaplan,et al.  Impaired development of human Th1 cells in patients with deficient expression of STAT4. , 2009, Blood.

[128]  R. Loeser,et al.  Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes. , 2009, Arthritis and rheumatism.

[129]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[130]  K. Ho,et al.  Growth hormone receptor modulators , 2009, Reviews in Endocrine and Metabolic Disorders.

[131]  Willis X. Li.  Canonical and non-canonical JAK-STAT signaling. , 2008, Trends in cell biology.

[132]  A. Giordano,et al.  Leptin signaling in breast cancer: An overview , 2008, Journal of cellular biochemistry.

[133]  David E Levy,et al.  IFNgamma signaling-does it mean JAK-STAT? , 2008, Cytokine & growth factor reviews.

[134]  Qiang Zhou,et al.  Structures and biological functions of IL-31 and IL-31 receptors. , 2008, Cytokine & growth factor reviews.

[135]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[136]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[137]  J. Renauld,et al.  IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis , 2008, Cell Death and Differentiation.

[138]  Daniel Birnbaum,et al.  Reasons for breast cancer heterogeneity , 2008, Journal of biology.

[139]  M. Yuen,et al.  Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1. , 2008, Cancer letters.

[140]  T. Macdonald,et al.  Autocrine Regulation of IL-21 Production in Human T Lymphocytes1 , 2008, The Journal of Immunology.

[141]  F. Schmidt.  Meta-Analysis , 2008 .

[142]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[143]  U. Vinkemeier,et al.  STAT nuclear translocation: potential for pharmacological intervention , 2007, Expert opinion on therapeutic targets.

[144]  G. Tiscia,et al.  A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. , 2007, Blood.

[145]  J. Guh,et al.  Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. , 2007, American journal of physiology. Renal physiology.

[146]  M. Mönnigmann,et al.  Nucleocytoplasmic shuttling of persistently activated STAT3 , 2007, Journal of Cell Science.

[147]  D. Gary Gilliland,et al.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.

[148]  K. Shokat,et al.  A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.

[149]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[150]  M. Waterfield,et al.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. , 2007, Cancer research.

[151]  Ye Zheng,et al.  Distinct Roles of Different NF-κB Subunits in Regulating Inflammatory and T Cell Stimulatory Gene Expression in Dendritic Cells1 , 2007, The Journal of Immunology.

[152]  G. Uzé,et al.  IL-28 and IL-29: newcomers to the interferon family. , 2007, Biochimie.

[153]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[154]  W. Vainchenker,et al.  Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. , 2007, Blood.

[155]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[156]  Guohua Yang,et al.  IFITM1 plays an essential role in the antiproliferative action of interferon-γ , 2007, Oncogene.

[157]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[158]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[159]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[160]  Eric M. Sandberg,et al.  Jak2 tyrosine kinase , 2007, Cell Biochemistry and Biophysics.

[161]  J. Darnell,et al.  Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. , 2006, Genes & development.

[162]  Xiaomeng Zhang,et al.  The multiple roles of Id-1 in cancer progression. , 2006, Differentiation; research in biological diversity.

[163]  A. Baldwin,et al.  Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.

[164]  Sandra A. Moore,et al.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. , 2006, Blood.

[165]  Jing Ma,et al.  Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements , 2006 .

[166]  D. McConkey,et al.  Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells , 2006, Angiogenesis.

[167]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[168]  Takuma Hayashi,et al.  The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-γ inducibility of TAP1 and LMP2 , 2006, Oncogene.

[169]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[170]  T. Nakamura,et al.  Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors , 2006, Oncogene.

[171]  J. Ihle,et al.  A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. , 2006, Cytokine.

[172]  C. Lavigne,et al.  The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. , 2006, Biochemical and biophysical research communications.

[173]  M. Gobbi,et al.  Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. , 2006, Blood.

[174]  G. Watkins,et al.  Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer , 2006, Annals of Surgical Oncology.

[175]  D. Frank,et al.  Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. , 2006, Cancer research.

[176]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[177]  M. Kaplan,et al.  The role of constitutively active Stat6 in leukemia and lymphoma. , 2006, Critical reviews in oncology/hematology.

[178]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[179]  G. Longmore.  A unique role for Stat5 in recovery from acute anemia. , 2006, The Journal of clinical investigation.

[180]  D. Elashoff,et al.  Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[181]  K. Anderson,et al.  Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside , 2005, Leukemia.

[182]  S. Gendler,et al.  Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis , 2005, Oncogene.

[183]  Hua Yu,et al.  Role of Stat3 in Regulating p53 Expression and Function , 2005, Molecular and Cellular Biology.

[184]  Lothar Hennighausen,et al.  Information networks in the mammary gland , 2005, Nature Reviews Molecular Cell Biology.

[185]  S. Constantinescu,et al.  Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability* , 2005, Journal of Biological Chemistry.

[186]  P. Murray.  The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[187]  A. Masamune,et al.  Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. , 2005, World journal of gastroenterology.

[188]  Kevin M. McBride,et al.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[189]  K. Ogino,et al.  Extracellular signal-dependent nuclear import of STAT3 is mediated by various importin alphas. , 2005, Biochemical and biophysical research communications.

[190]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[191]  V. Kim.  MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[192]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[193]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[194]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[195]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[196]  L. Wen,et al.  Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells , 2005, Acta Pharmacologica Sinica.

[197]  Rama,et al.  A Novel Quinazoline Derivative with Potent Cytotoxic Activity against Human Glioblastoma Cells , 2005 .

[198]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[199]  B. Little,et al.  Identification of the first patient with a confirmed mutation of the JAK-STAT system , 2005, Pediatric Nephrology.

[200]  Mark J. Bowser,et al.  EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[201]  F. Finkelman,et al.  Interleukin‐4‐ and interleukin‐13‐mediated host protection against intestinal nematode parasites , 2004, Immunological reviews.

[202]  N. Reich,et al.  STAT2 Nuclear Trafficking* , 2004, Journal of Biological Chemistry.

[203]  C. Deng,et al.  Inactivation of Stat5 in Mouse Mammary Epithelium during Pregnancy Reveals Distinct Functions in Cell Proliferation, Survival, and Differentiation , 2004, Molecular and Cellular Biology.

[204]  P. Heinrich,et al.  Janus Kinase (Jak) Subcellular Localization Revisited , 2004, Journal of Biological Chemistry.

[205]  David Baltimore,et al.  One Nucleotide in a κB Site Can Determine Cofactor Specificity for NF-κB Dimers , 2004, Cell.

[206]  S. Kotenko,et al.  Full house: 12 receptors for 27 cytokines. , 2004, International immunopharmacology.

[207]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[208]  Shulin Li,et al.  Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[209]  T. Ouchi,et al.  STAT1-induced Apoptosis Is Mediated by Caspases 2, 3, and 7* , 2004, Journal of Biological Chemistry.

[210]  R. Puri,et al.  Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. , 2004, Molecular cancer therapeutics.

[211]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[212]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[213]  M. Ricote,et al.  Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study , 2003, Breast Cancer Research.

[214]  R. Lahesmaa,et al.  Identification of Novel IL-4/Stat6-Regulated Genes in T Lymphocytes1 , 2003, The Journal of Immunology.

[215]  B. Little,et al.  Growth hormone insensitivity associated with a STAT5b mutation. , 2003, The New England journal of medicine.

[216]  L. Ivashkiv,et al.  The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? , 2003, Arthritis and rheumatism.

[217]  W. Jiang,et al.  Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. , 2003, Histology and histopathology.

[218]  J. Karras,et al.  macrophage survival Serine phosphorylation of STAT 3 is essential for Mcl-1 expression and , 2003 .

[219]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[220]  S. Akira,et al.  IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages , 2003, Nature Immunology.

[221]  L. Nie,et al.  STAT5‐induced Id‐1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ , 2003, The EMBO journal.

[222]  C. R. Lankford,et al.  A unique role for IL‐23 in promoting cellular immunity , 2003, Journal of leukocyte biology.

[223]  S. Aaronson,et al.  Implications for Cancer Therapy , 2003 .

[224]  C. Vosshenrich,et al.  Interleukin signaling , 2002, Current Biology.

[225]  M. Cathcart,et al.  IL‐13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats , 2002, Journal of leukocyte biology.

[226]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[227]  M. White,et al.  Interleukin-4-mediated Protection of Primary B Cells from Apoptosis through Stat6-dependent Up-regulation of Bcl-xL* , 2002, The Journal of Biological Chemistry.

[228]  D. Frank,et al.  The role of STATs in apoptosis. , 2002, Current molecular medicine.

[229]  K. Arai,et al.  Stat5B Shuttles Between Cytoplasm and Nucleus in a Cytokine-Dependent and -Independent Manner1 , 2002, The Journal of Immunology.

[230]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[231]  C. Bucana,et al.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells , 2002, Oncogene.

[232]  S. Pestka,et al.  Interferon‐γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death , 2001, Journal of leukocyte biology.

[233]  P. Subramaniam,et al.  So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. , 2001, Cytokine.

[234]  J. Herrington,et al.  Signaling pathways activated by the growth hormone receptor , 2001, Trends in Endocrinology & Metabolism.

[235]  Steven M. Holland,et al.  Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation , 2001, Science.

[236]  J. Stankova,et al.  G-protein-independent Activation of Tyk2 by the Platelet-activating Factor Receptor* , 2001, The Journal of Biological Chemistry.

[237]  M. Runge,et al.  Thrombin Regulates Vascular Smooth Muscle Cell Growth and Heat Shock Proteins via the JAK-STAT Pathway* , 2001, The Journal of Biological Chemistry.

[238]  Mario Mellado,et al.  Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.

[239]  D. Levy,et al.  Cooperation between STAT3 and c-jun suppresses Fas transcription. , 2001, Molecular cell.

[240]  D. Conklin,et al.  Interleukin 20 Discovery, Receptor Identification, and Role in Epidermal Function , 2001, Cell.

[241]  T. Savarese,et al.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.

[242]  C. Schindler,et al.  Immune response in Stat2 knockout mice. , 2000, Immunity.

[243]  S. Rane,et al.  Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[244]  J. Renauld,et al.  Role of insulin receptor substrate‐2 in interleukin‐9‐dependent proliferation , 2000, FEBS letters.

[245]  M. B. Harris,et al.  Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. , 2000, The Biochemical journal.

[246]  H. Johnson,et al.  Down-Regulation of neu/HER-2 by Interferon-γ in Prostate Cancer Cells , 2000 .

[247]  C. Xiao,et al.  Nuclear targeting signal recognition: a key control point in nuclear transport? , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[248]  K. Bernstein,et al.  Jak2 Acts as Both a STAT1 Kinase and as a Molecular Bridge Linking STAT1 to the Angiotensin II AT1 Receptor* , 2000, The Journal of Biological Chemistry.

[249]  S. Pestka,et al.  Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes , 2000, Oncogene.

[250]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[251]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[252]  L. Koenderman,et al.  STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. , 2000, Molecular cell biology research communications : MCBRC.

[253]  Mikhail Chernov,et al.  Regulation of c‐myc expression by IFN‐γ through Stat1‐dependent and ‐independent pathways , 2000 .

[254]  H. Johnson,et al.  Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. , 2000, Cancer research.

[255]  A. Yoshimura,et al.  The Jak-Stat pathway in normal and perturbed hematopoiesis. , 2000, Blood.

[256]  C. Martínez-A,et al.  The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[257]  A. Mui,et al.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells , 1999, The EMBO journal.

[258]  Jonathan A. Cooper,et al.  STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation , 1999, Oncogene.

[259]  S. Akira,et al.  Interleukin-10 Receptor Signaling through the JAK-STAT Pathway , 1999, The Journal of Biological Chemistry.

[260]  P. D. Smith,et al.  Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA , 1999, British Journal of Cancer.

[261]  J. Ritz,et al.  Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling , 1999, Nature Medicine.

[262]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response , 1999, Oncogene.

[263]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[264]  M. David,et al.  Role of the STAT1-SH2 Domain and STAT2 in the Activation and Nuclear Translocation of STAT1* , 1998, The Journal of Biological Chemistry.

[265]  L. Velloso,et al.  Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. , 1998, Cardiovascular research.

[266]  Angel F. Lopez,et al.  Mechanism of Activation of the GM‐CSF, IL‐3, and IL‐5 Family of Receptors , 1998, Stem cells.

[267]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[268]  X. P. Liu,et al.  4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[269]  B. Mathey-Prevot,et al.  Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors , 1998 .

[270]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[271]  A. Cumano,et al.  Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.

[272]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[273]  T. Zhu,et al.  Growth Hormone Stimulates the Tyrosine Phosphorylation and Association of p125 Focal Adhesion Kinase (FAK) with JAK2 , 1998, The Journal of Biological Chemistry.

[274]  K. Takatsu,et al.  JAK2 and JAK1 Constitutively Associate With an Interleukin-5 (IL-5) Receptor α and βc Subunit, Respectively, and Are Activated Upon IL-5 Stimulation , 1998 .

[275]  K. Takatsu,et al.  JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation. , 1998, Blood.

[276]  N. Reich,et al.  Distinct STAT Structure Promotes Interaction of STAT2 with the p48 Subunit of the Interferon-α-stimulated Transcription Factor ISGF3* , 1997, The Journal of Biological Chemistry.

[277]  P. Kelly,et al.  The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor , 1997, Molecular and Cellular Endocrinology.

[278]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[279]  Y. Yazaki,et al.  Antisense Repression of Proto-oncogene c-Cbl Enhances Activation of the JAK-STAT Pathway but Not the Ras Pathway in Epidermal Growth Factor Receptor Signaling* , 1997, The Journal of Biological Chemistry.

[280]  T. Roberts,et al.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways , 1997, Molecular and cellular biology.

[281]  J. Ceuppens,et al.  CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model , 1996, Immunological reviews.

[282]  P. Doherty,et al.  Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells , 1996, Nature.

[283]  W. Paul,et al.  Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene , 1996, Nature.

[284]  M. Vignais,et al.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins , 1996, Molecular and cellular biology.

[285]  D. Görlich,et al.  Nucleocytoplasmic Transport , 1996, Science.

[286]  W. Leonard,et al.  Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[287]  G. Stark,et al.  Kinase‐negative mutants of JAK1 can sustain interferon‐gamma‐inducible gene expression but not an antiviral state. , 1996, The EMBO journal.

[288]  S. Stafford,et al.  The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils. , 1995, Journal of immunology.

[289]  B. Berk,et al.  Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor , 1995, Nature.

[290]  D. Barber,et al.  Erythropoietin and interleukin-2 activate distinct JAK kinase family members , 1994, Molecular and cellular biology.

[291]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[292]  J. Darnell,et al.  Stat3 and Stat4: members of the family of signal transducers and activators of transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[293]  B. Groner,et al.  Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. , 1994, The EMBO journal.

[294]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[295]  J. Darnell,et al.  A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. , 1993, Science.

[296]  J. Darnell,et al.  Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. , 1992, Science.

[297]  A. Andres,et al.  JAK2, a third member of the JAK family of protein tyrosine kinases. , 1992, Oncogene.

[298]  T. Shows,et al.  tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.

[299]  T. Yokota,et al.  Cytokines: coordinators of immune and inflammatory responses. , 1990, Annual review of biochemistry.

[300]  H. Lodish,et al.  Erythropoietin receptor and interleukin-2 receptor β chain: A new receptor family , 1989, Cell.

[301]  H. Lodish,et al.  Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. , 1989, Cell.

[302]  Z. Danilevicius.  New application for old drug. , 1976, JAMA.

[303]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.